Projects per year
Personal profile
Headline
PROFESSOR | Medicine, Gastroenterology
Fingerprint
Dive into the research topics where Bruce E. Sands is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Translating Scientific Evidence into Practice using Digital Medicine and Electronic Patient Reported Outcomes
Sands, B. E., Atreja, A., Atreja, A. A., Rizk, M. M., Regueiro, M. D. & Sands, B. E.
National Center for Advancing Translational Sciences
20/04/20 → 31/03/23
Project: Research
-
Research Training in Digestive Diseases
Chung, R. R. T., Chung, R. T., Podolsky, D. D. K., Goessling, W., Isselbacher, K. K. J., Podolsky, D. K., Sands, B. E., Goessling, W. W. & Xavier, R. J.
National Institute of Diabetes and Digestive and Kidney Diseases
1/07/86 → 30/06/23
Project: Research
-
CLINICAL/TISSUE CORE
National Institute of Diabetes and Digestive and Kidney Diseases
1/01/11 → 31/12/15
Project: Research
-
IMURAN Dose Ranging Study in Crohn's Disease
U.S. Food and Drug Administration
30/09/05 → 29/09/07
Project: Research
-
Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial
Zisman-Ilani, Y., Thompson, K. D., Siegel, L. S., Mackenzie, T., Crate, D. J., Korzenik, J. R., Melmed, G. Y., Kozuch, P., Sands, B. E., Rubin, D. T., Regueiro, M. D., Cross, R., Wolf, D. C., Hanson, J. S., Schwartz, R. M., Vrabie, R., Kreines, M. D., Scherer, T., Dubinsky, M. C. & Siegel, C. A., Jan 2023, In: Alimentary Pharmacology and Therapeutics. 57, 2, p. 205-214 10 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis
Dulai, P. S., Feagan, B. G., Sands, B. E., Chen, J., Lasch, K. & Lirio, R. A., Feb 2023, In: Clinical Gastroenterology and Hepatology. 21, 2, p. 456-466.e7Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Reply
Cohen, B. L., Fleshner, P. & Sands, B. E., Feb 2023, In: Gastroenterology. 164, 2, p. 308-309 2 p.Research output: Contribution to journal › Letter › peer-review
Open Access -
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
Vermeire, S., Sands, B. E., Tilg, H., Tulassay, Z., Kempinski, R., Danese, S., Bunganič, I., Nitcheu, J., Santo, J., Scherrer, D., Biguenet, S., Ehrlich, H. J., Steens, J. M., Gineste, P. & Sandborn, W. J., Nov 2022, In: The Lancet Gastroenterology and Hepatology. 7, 11, p. 1024-1035 12 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease (Nature Communications, (2020), 11, 1, (995), 10.1038/s41467-019-14275-y)
COLORS in IBD group investigators, Oxford IBD cohort study investigators, INTERVAL Study, Swiss IBD Cohort Investigators, UK IBD Genetics Consortium & NIDDK IBD Genetics Consortium, Dec 2022, In: Nature Communications. 13, 1, 3576.Research output: Contribution to journal › Comment/debate
Open Access
Press / Media
-
For Ulcerative Colitis, Two First-In-Class Candidates and an Interleukin-23 Competition
1/02/23
1 item of Media coverage
Press/Media
-
-
Bruce Sands, MD, on the QUASAR Study of Guselkumab in Ulcerative Colitis
27/12/22
1 item of Media coverage
Press/Media
-
-
Bruce Sands, MD, MS: Guselkumab Data Continues to Impress at ACG
21/11/22
1 item of Media coverage
Press/Media